RankingsPricing
  1. US-listed companies
  2. NeuBase Therapeutics, Inc.
  3. Financials
  4. Capital expenditures

NeuBase Therapeutics, Inc.NBSE

Market cap
$1.41M
P/E ratio
SummaryFinancials
Period EndCapital expenditures (Million USD)YoY (%)
Sep 30, 2022-0-67.21%
Sep 30, 2021-1+100.67%
Sep 30, 2020-1+57.47%
Sep 30, 2019-0+9318.58%
Sep 30, 2017-0-66.69%
Sep 30, 2016-0-92.15%
Sep 30, 2015-0+216.58%
Sep 30, 2013-0+0.00%
Sep 30, 2012-0+133.52%
Sep 30, 2011-0

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating income Operating expenses Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSAdjusted EPSDividend payout ratio (%)Dividend per shareAdjusted DPSEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)